BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of cutaneous T cell lymphoma. Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome.
Sobi will pay Innate Pharma $75 million, payable on closing. Innate will be eligible to receive up to a further $40 million in respect of near-term development milestones connected to Sezary syndrome. Innate will be eligible to receive up to $465 million related to the option for Sobi to get full development rights and to future regulatory and commercial milestones. Innate will be eligible to receive tiered double-digit royalties on net sales.
Swedish Orphan Biovitrum shares are trading at 458.80 Swedish kronor on Nasdaq Stockholm, up 1.24%. At previous close on Euronext Paris exchange, Innate shares were trading at 1.51 euros.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
